Responses
Regular and young investigator award abstracts
Clinical trials in progress
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.